Results 181 to 190 of about 69,250 (228)
Reorganization of the sensorimotor cortex in patients with Ph-negative myeloproliferative neoplasms according to functional MRI. [PDF]
Front NeurosciKuznetsova PI +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2022
Molecular laboratory investigations for myeloproliferative neoplasm (MPN) can ideally be divided into two distincts groups, those for the detection of the BCR-ABL rearrangement (suspect of chronic myeloid leukemia) and those for the variants determination of the driver genes of the negative Philadelphia forms (MPN Ph neg).
Alice, Moncada, Alessandro, Pancrazzi
openaire +2 more sources
Molecular laboratory investigations for myeloproliferative neoplasm (MPN) can ideally be divided into two distincts groups, those for the detection of the BCR-ABL rearrangement (suspect of chronic myeloid leukemia) and those for the variants determination of the driver genes of the negative Philadelphia forms (MPN Ph neg).
Alice, Moncada, Alessandro, Pancrazzi
openaire +2 more sources
Management of Myeloproliferative Neoplasms (MPNs)
Journal of Oncology Pharmacy Practice, 2022Purpose To provide up to date guidance, practice recommendations and highlight barriers to medication adherence in the long-term management of chronic myeloproliferative neoplasms (MPNs). Aim Current drug therapy for MPN is not curative and has not been shown to prolong survival.
Zubeir Nurgat, Myer Lawrence
openaire +2 more sources
Current Hematologic Malignancy Reports, 2017
Chronic myeloproliferative neoplasms (MPN) characteristically arise from a somatic mutation in the pluripotent hematopoietic stem cell, and most common recurring mutations are in the JAK2, CALR, and cMPL genes. However, these mutations are not founder mutations, but mainly drive the disease phenotype and a pre-existing germline predisposition has been ...
Tsewang, Tashi +2 more
openaire +2 more sources
Chronic myeloproliferative neoplasms (MPN) characteristically arise from a somatic mutation in the pluripotent hematopoietic stem cell, and most common recurring mutations are in the JAK2, CALR, and cMPL genes. However, these mutations are not founder mutations, but mainly drive the disease phenotype and a pre-existing germline predisposition has been ...
Tsewang, Tashi +2 more
openaire +2 more sources
Current Hematologic Malignancy Reports, 2013
A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases.
Finazzi, G +2 more
openaire +2 more sources
A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases.
Finazzi, G +2 more
openaire +2 more sources
The roles of sex and genetics in the MPN
2022The Philadelphia chromosome negative myeloproliferative neoplasms(MPNs), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are acquired hematopoietic stem cell disorders driven by activating mutations of intracellular signal transduction pathways that control the production of circulating blood cells.
Alison R, Moliterno, Evan M, Braunstein
openaire +2 more sources
An Immune Dysregulation in MPN
Current Hematologic Malignancy Reports, 2014Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose to MPNs, autoimmune disorders or ...
openaire +2 more sources
Clinical Predictors of Outcome in MPN
Hematology/Oncology Clinics of North America, 2012Myeloproliferative neoplasms include 3 diseases: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET are dominated by a high risk of thrombosis and a late risk of clonal evolution into secondary MF and acute myeloid leukemia.
PASSAMONTI, FRANCESCO +4 more
openaire +4 more sources